INDV-1000

Last updated

INDV-1000
Clinical data
Other namesINDV1000
Routes of
administration 		Unspecified [1]
Drug class GABAB receptor positive allosteric modulator

INDV-1000 is a GABAB receptor positive allosteric modulator (PAM) which is under development for the treatment of substance-related disorders. [1] [2] [3] Its route of administration is unspecified. [1] The drug is under development by Indivior in partnership with Addex Therapeutics. [1] [2] [3] As of April 2024, it is in the preclinical research stage of development. [1] [2] [3] The chemical structure of INDV-1000 does not yet appear to have been disclosed. [1] It is one of a limited number of known GABAB receptor PAMs as of 2024. [4] [5]

See also

References

  1. 1 2 3 4 5 6 "INDV 1000". AdisInsight. 29 February 2024. Retrieved 28 January 2026.
  2. 1 2 3 "Delving into the Latest Updates on INDV-1000 with Synapse". Synapse. 27 May 2025. Retrieved 28 January 2026.
  3. 1 2 3 Deswal P (30 April 2024). "Addex stock tanks after lead drug flops in Phase II epilepsy trial". Clinical Trials Arena. Retrieved 28 January 2026. Addex has also partnered with Indivior and is developing the gamma-aminobutyric acid subtype B (GABA-B) PAM asset, INDV-1000. The therapy is in preclinical development, with plans to select drug candidates for an investigational new drug (IND), enabling studies in June for the substance use disorder and chronic cough programs.
  4. ↑ Colombo G (March 2024). "Positive allosteric modulators of the GABAB receptor: a new class of ligands with therapeutic potential for alcohol use disorder". Alcohol and Alcoholism. 59 (3) agae018. doi:10.1093/alcalc/agae018. PMID   38566580.
  5. ↑ Mugnaini C, Corelli F (2024). "Recent Advances on the Chemistry of GABAB Receptor Allosteric Modulators". GABAB Receptor. The Receptors. Cham: Springer International Publishing. pp. 169–200. doi:10.1007/978-3-031-67148-7_8. ISBN   978-3-031-67147-0 . Retrieved 28 January 2026.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.